Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy

被引:58
作者
Claessen, Kim M. J. A.
Appelman-Dijkstra, Natasha M.
Adoptie, Desiree M. M. M.
Roelfsema, Ferdinand
Smit, Johannes W. A.
Biermasz, Nienke R.
Pereira, Alberto M.
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Ctr Endocrine Tumors Leiden, NL-2300 RC Leiden, Netherlands
关键词
BONE-MINERAL DENSITY; HYPOPITUITARY PATIENTS; REPLACEMENT THERAPY; CARDIOVASCULAR-DISEASE; ENDOCRINE REGULATION; PREMATURE MORTALITY; CHOLESTEROL; PREVALENCE; METAANALYSIS; ASSOCIATION;
D O I
10.1210/jc.2012-2940
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background: The metabolic effects of recombinant human GH (rhGH) therapy in adults are well-documented in the short term. The effects of long-term rhGH therapy beyond 5 yr on metabolic parameters are presently unknown. Objective: The aim of the study was to evaluate the long-term effects of rhGH treatment on biochemical and anthropometric parameters in a large cohort of GH-deficient adults. Methods: Ninety-eight GH-deficient adult patients treated with rhGH for at least 10 yr were included (mean age, 59.4 yr; 50% female). Total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, anthropometric parameters, IGF-I, and glucose were evaluated at baseline and after 5, 10, and 15 yr of treatment. In addition, the prevalence of the metabolic syndrome (MS) and the incidence of cardiovascular events were assessed. Results: Total cholesterol and low-density lipoprotein cholesterol concentrations were lower, and high-density lipoprotein cholesterol levels were significantly higher during long-term rhGH replacement when compared to baseline (all P < 0.001). Both waist circumference (P < 0.001) and body mass index (P = 0.018) were significantly higher after 10 yr, as were fasting plasma glucose levels (P < 0.001). No significant changes were observed in triglycerides, waist-to- hip ratio, and blood pressure during follow-up. In the subset of patients with 15-yr rhGH treatment (n = 43), generally similar metabolic effects were found. MS prevalence was increased after 10 yr of rhGH treatment (57.1 vs. 32.7%; P < 0.001), especially in males (69.4 vs. 32.7%; P < 0.001). Conclusion: Despite improvement of several cardiovascular risk factors, MS prevalence increased significantly during rhGH treatment. The effect of long-term rhGH treatment on overall cardiovascular risk profile needs to be established in a larger cohort. (J Clin Endocrinol Metab 98:352-361, 2013)
引用
收藏
页码:352 / 361
页数:10
相关论文
共 44 条
[1]
Isolated growth hormone (GH) deficiency in adult patients:: Baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients.: A sub-analysis of the KIMS database [J].
Abs, R ;
Mattsson, AF ;
Bengtsson, BÅ ;
Feldt-Rasmussen, U ;
Góth, MI ;
Koltowska-Häggström, M ;
Monson, JP ;
Verhelst, J ;
Wilton, P .
GROWTH HORMONE & IGF RESEARCH, 2005, 15 (05) :349-359
[2]
[Anonymous], 2001, JAMA, V285, P2486
[3]
Prevalence of Metabolic Syndrome in Adult Hypopituitary Growth Hormone (GH)-Deficient Patients Before and After GH Replacement [J].
Attanasio, Andrea F. ;
Mo, Daojun ;
Erfurth, Eva Marie ;
Tan, Meng ;
Ho, Ken Y. ;
Kleinberg, David ;
Zimmermann, Alan G. ;
Chanson, Philippe .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (01) :74-81
[4]
The Critical Role of Metabolic Pathways in Aging [J].
Barzilai, Nir ;
Huffman, Derek M. ;
Muzumdar, Radhika H. ;
Bartke, Andrzej .
DIABETES, 2012, 61 (06) :1315-1322
[5]
Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality [J].
Burgers, Anne Marij G. ;
Biermasz, Nienke R. ;
Schoones, Jan W. ;
Pereira, Alberto M. ;
Renehan, Andrew G. ;
Zwahlen, Marcel ;
Egger, Matthias ;
Dekkers, Olaf M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09) :2912-2920
[6]
Effects of 7 years of growth hormone replacement therapy in hypopituitary adults [J].
Chrisoulidou, A ;
Beshyah, SA ;
Rutherford, O ;
Spinks, TJ ;
Mayet, J ;
Kyd, P ;
Anyaoku, V ;
Haida, A ;
Ariff, B ;
Murphy, M ;
Thomas, E ;
Robinson, S ;
Foale, R ;
Johnston, DG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3762-3769
[7]
COLE TJ, 1990, EUR J CLIN NUTR, V44, P45
[8]
The relationship between glucose and incident cardiovascular events [J].
Coutinho, M ;
Gerstein, HC ;
Wang, Y ;
Yusuf, S .
DIABETES CARE, 1999, 22 (02) :233-240
[9]
Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study [J].
Danilowicz, Karina ;
Bruno, Oscar Domingo ;
Manavela, Marcos ;
Gomez, Reynaldo Manuel ;
Barkan, Ariel .
PITUITARY, 2008, 11 (03) :279-285
[10]
Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency [J].
Elbornsson, Mariam ;
Gotherstrom, Galina ;
Bosaeus, Ingvar ;
Bengtsson, Bengt-Ake ;
Johannsson, Gudmundur ;
Svensson, Johan .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 166 (05) :787-795